Document Detail


Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
MedLine Citation:
PMID:  18753306     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There are high expectations about the capabilities of pharmacogenetics to tailor psychotropic treatment and "personalize" treatment. While a large number of associations, with generally small effect size, have been discovered, a "test" with widespread use and adoption is still missing. A more realistic picture, recognizing the important contribution of clinical and environmental factors toward overall clinical outcome has emerged. In this emerging view, genetic findings, if considered individually, may have limited clinical applications. Thus, in recent years, combinations of information in several genes have been used for the selection of appropriate therapeutic doses and for the prediction of agranulocytosis, hyperlipidemia, and response to antipsychotic and antidepressant medications. While these tests based on multiple genes show greater predictive ability than individual allele tests, their net impact on clinical consequence and costs is limited, thus leading to limited penetration into widespread clinical use. As one looks at other branches of medicine, there are successful examples of pharmacogenetic tests guiding treatment, and thus, it is reasonable to hope that with the incorporation of clinical and environmental information and the identification of new genes drawn from genome-wide analysis, will improve the predictive utility of these tests leading to their increased use by clinicians.
Authors:
Maria J Arranz; Shitij Kapur
Related Documents :
25313596 - Advanced topics in neuropsychological assessment following sport-related concussion.
20378936 - Diagnostic validity of helical ct compared to ultrasonography in renal-ureteral colic.
25326816 - Choosing algorithms for tb screening: a modelling study to compare yield, predictive va...
24285736 - Xpert mtb/rif version g4 for the identification of rifampicin resistant tuberculosis in...
25066276 - Development and clinical testing of a simple, low-density gel element array for influen...
8816936 - Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco.
Publication Detail:
Type:  Journal Article; Review     Date:  2008-08-27
Journal Detail:
Title:  Schizophrenia bulletin     Volume:  34     ISSN:  0586-7614     ISO Abbreviation:  Schizophr Bull     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-14     Completed Date:  2009-02-03     Revised Date:  2014-02-19    
Medline Journal Info:
Nlm Unique ID:  0236760     Medline TA:  Schizophr Bull     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1130-44     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antipsychotic Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Cytochrome P-450 Enzyme System / genetics
Dose-Response Relationship, Drug
Gene Expression / genetics
Genetic Testing
Humans
Pharmacogenetics / methods*
Phenotype
Schizophrenia / drug therapy*,  genetics*
Schizophrenic Psychology
Social Environment
Treatment Outcome
Grant Support
ID/Acronym/Agency:
G0701748//Medical Research Council
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 9035-51-2/Cytochrome P-450 Enzyme System
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The impact of orthodontic treatment on the quality of life in adolescents: a case-control study.
Next Document:  First-rank symptoms in schizophrenia: reexamining mechanisms of self-recognition.